MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Cancer; Solid Tumor; Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer Interventions: Drug: FT538; Biological: Enoblituzumab Sponsor: Masonic Cancer Center, University of Minnesota Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Fallopian Tube Cancer | Ovarian Cancer | Ovaries | Peritoneal Cancer | Research